A small, well-covered dividend from a life-sciences giant — leverage is the number to watch. The $0.47 quarterly dividend ($1.88 annualized) is 10.1% of fiscal 2025 free cash flow, and the dividend has risen every year in the series shown, from $0.60 in 2017 to $1.72 in 2025, with no cut. Leverage of 2.9× net debt to adjusted EBITDA at the end of the third quarter of 2026 is inside the §3 pass band; the company-reported gross-debt figure of 3.4× sits in the caution band. The 0.27% yield is under 1%, which grades the card warn under §1.
Key risk: Leverage — a debt-funded acquisition program leaves less room if research funding or instrument demand slows.
Changes if: The yield rises above 1% through raises, or net leverage falls below 2×.
- ✓FCF payout (§3) 10.1% of FY2025 free cash flow — inside the 60% pass band.
- ✓Dividend history (§3) Annual totals rise every year 2017–2025; no cut.
- ✓Leverage (§3) 2.9× net debt / adjusted EBITDA (company-reported, Q3 2026) — inside the 3× pass line; gross-debt 3.4× in the caution band, noted.
- !Yield (§1) 0.27% — under 1%, graded warn as a growth holding.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.